Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	ubiquitin-like protein peptidase activity	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP10 USP17L17 OTUD7A USP17L6P USP17L22 SENP7 USP17L13	1.57e-14	137	159	16	GO:0019783
GeneOntologyMolecularFunction	cysteine-type deubiquitinase activity	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP10 USP17L17 OTUD7A USP17L6P USP17L22 USP17L13	1.77e-14	114	159	15	GO:0004843
GeneOntologyMolecularFunction	deubiquitinase activity	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP10 USP17L17 OTUD7A USP17L6P USP17L22 USP17L13	6.34e-14	124	159	15	GO:0101005
GeneOntologyMolecularFunction	cysteine-type peptidase activity	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP10 USP17L17 OTUD7A USP17L6P USP17L22 SENP7 USP17L13	3.13e-12	192	159	16	GO:0008234
GeneOntologyMolecularFunction	peptidase activity	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 PRSS58 CFB USP17L18 USP10 RNPEP USP17L17 TMPRSS3 OTUD7A USP17L6P CORIN ERVK-19 LTA4H USP17L22 SENP7 USP17L13	2.31e-09	654	159	23	GO:0008233
GeneOntologyMolecularFunction	ribosomal protein S6 kinase activity	RPS6KA4 RPS6KA1 RPS6KA3 RPS6KA6	1.33e-07	7	159	4	GO:0004711
GeneOntologyMolecularFunction	protein tyrosine phosphatase activity	DUSP18 PTPN3 PTPN4 PTPRD PTPRF PTPRZ1 TIMM50	1.86e-05	103	159	7	GO:0004725
GeneOntologyMolecularFunction	isoleucine-tRNA ligase activity	IARS1 IARS2	6.30e-05	2	159	2	GO:0004822
GeneOntologyMolecularFunction	hydrolase activity, acting on ester bonds	DUSP18 ERCC5 IARS1 ENPP2 WRN PTPN3 PTPN4 IARS2 PTPRD PTPRF PTPRZ1 PAFAH2 TIMM50 PLA2G4F SLFN11 PLCG1 CNOT1 DAGLA	7.91e-05	807	159	18	GO:0016788
GeneOntologyMolecularFunction	transmembrane receptor protein tyrosine phosphatase activity	PTPRD PTPRF PTPRZ1	3.10e-04	17	159	3	GO:0005001
GeneOntologyMolecularFunction	transmembrane receptor protein phosphatase activity	PTPRD PTPRF PTPRZ1	3.10e-04	17	159	3	GO:0019198
GeneOntologyMolecularFunction	minus-end-directed microtubule motor activity	DNAH3 DNAH1 DNAH6	3.70e-04	18	159	3	GO:0008569
GeneOntologyMolecularFunction	phosphoprotein phosphatase activity	DUSP18 PTPN3 PTPN4 PTPRD PTPRF PTPRZ1 TIMM50	8.10e-04	189	159	7	GO:0004721
GeneOntologyBiologicalProcess	protein modification by small protein removal	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP10 USP17L17 OTUD7A USP17L6P USP17L22 SENP7 USP17L13	1.74e-14	144	157	16	GO:0070646
GeneOntologyBiologicalProcess	protein deubiquitination	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP10 USP17L17 OTUD7A USP17L6P USP17L22 USP17L13	3.73e-14	125	157	15	GO:0016579
GeneOntologyBiologicalProcess	protein deubiquitination involved in ubiquitin-dependent protein catabolic process	USP17L24 OTUD7A USP17L6P	2.36e-05	8	157	3	GO:0071947
GeneOntologyBiologicalProcess	isoleucyl-tRNA aminoacylation	IARS1 IARS2	5.76e-05	2	157	2	GO:0006428
GeneOntologyCellularComponent	cell projection membrane	TMEM67 NCKAP1 PIEZO1 PKD1L1 APC SSTR3 MAPK8IP3 SLC5A1 TTC8 HHIP MUC17 PTPRZ1 PLA2G4F PLCG1 DAGLA	1.02e-06	431	158	15	GO:0031253
GeneOntologyCellularComponent	inner dynein arm	DNAH3 DNAH1 DNAH6	4.89e-05	10	158	3	GO:0036156
GeneOntologyCellularComponent	leading edge membrane	NCKAP1 PIEZO1 APC MAPK8IP3 PTPRZ1 PLA2G4F PLCG1 DAGLA	2.02e-04	210	158	8	GO:0031256
GeneOntologyCellularComponent	Wnt signalosome	APC FZD1 RECK	2.21e-04	16	158	3	GO:1990909
GeneOntologyCellularComponent	endoplasmic reticulum membrane	VAPB TMEM67 USP17L21 USP17L12 COPB1 USP17L20 USP17L11 PIEZO1 USP17L5 USP17L10 USP17L19 USP17L18 CLCN4 USP17L17 TMPRSS3 PAFAH2 USP17L6P TRPM1 USP17L22 SEC23B USP17L13	7.55e-04	1293	158	21	GO:0005789
GeneOntologyCellularComponent	endoplasmic reticulum subcompartment	VAPB TMEM67 USP17L21 USP17L12 COPB1 USP17L20 USP17L11 PIEZO1 USP17L5 USP17L10 USP17L19 USP17L18 CLCN4 USP17L17 TMPRSS3 PAFAH2 USP17L6P TRPM1 USP17L22 SEC23B USP17L13	8.00e-04	1299	158	21	GO:0098827
GeneOntologyCellularComponent	axonemal dynein complex	DNAH3 DNAH1 DNAH6	8.62e-04	25	158	3	GO:0005858
GeneOntologyCellularComponent	ciliary membrane	TMEM67 PKD1L1 SSTR3 TTC8 HHIP	8.93e-04	98	158	5	GO:0060170
GeneOntologyCellularComponent	nuclear outer membrane-endoplasmic reticulum membrane network	VAPB TMEM67 USP17L21 USP17L12 COPB1 USP17L20 USP17L11 PIEZO1 USP17L5 USP17L10 USP17L19 USP17L18 CLCN4 USP17L17 TMPRSS3 PAFAH2 USP17L6P TRPM1 USP17L22 SEC23B USP17L13	1.05e-03	1327	158	21	GO:0042175
GeneOntologyCellularComponent	postsynaptic membrane	GRM3 CHRM2 MET PTPRF PTPRZ1 ELFN1 DAGLA MUSK EPHA4 EPHA7	1.05e-03	405	158	10	GO:0045211
GeneOntologyCellularComponent	postsynaptic density membrane	PTPRF PTPRZ1 ELFN1 DAGLA EPHA4 EPHA7	1.25e-03	157	158	6	GO:0098839
Domain	HABP4_PAI-RBP1	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L19 USP17L18 USP17L17 USP17L22 USP17L13	4.07e-20	16	156	11	PF04774
Domain	HABP4_PAIRBP1-bd	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L19 USP17L18 USP17L17 USP17L22 USP17L13	4.07e-20	16	156	11	IPR006861
Domain	USP_CS	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP10 USP17L17 USP17L22 USP17L13	8.10e-15	66	156	13	IPR018200
Domain	USP_1	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP10 USP17L17 USP17L22 USP17L13	1.83e-14	70	156	13	PS00972
Domain	UCH	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP10 USP17L17 USP17L22 USP17L13	2.22e-14	71	156	13	PF00443
Domain	USP_2	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP10 USP17L17 USP17L22 USP17L13	2.22e-14	71	156	13	PS00973
Domain	USP_3	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP10 USP17L17 USP17L22 USP17L13	2.69e-14	72	156	13	PS50235
Domain	USP_dom	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP10 USP17L17 USP17L22 USP17L13	2.69e-14	72	156	13	IPR028889
Domain	Peptidase_C19_UCH	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP10 USP17L17 USP17L22 USP17L13	2.69e-14	72	156	13	IPR001394
Domain	Ribosomal_S6_kinase_II	RPS6KA4 RPS6KA1 RPS6KA3 RPS6KA6	6.93e-08	6	156	4	IPR016239
Domain	PTPc	PTPN3 PTPN4 PTPRD PTPRF PTPRZ1	1.17e-05	36	156	5	SM00194
Domain	TYR_PHOSPHATASE_PTP	PTPN3 PTPN4 PTPRD PTPRF PTPRZ1	1.75e-05	39	156	5	PS50055
Domain	PTPase_domain	PTPN3 PTPN4 PTPRD PTPRF PTPRZ1	2.24e-05	41	156	5	IPR000242
Domain	Y_phosphatase	PTPN3 PTPN4 PTPRD PTPRF PTPRZ1	2.24e-05	41	156	5	PF00102
Domain	Tyr_Pase_AS	DUSP18 PTPN3 PTPN4 PTPRD PTPRF PTPRZ1	3.31e-05	73	156	6	IPR016130
Domain	Ile-tRNA-ligase	IARS1 IARS2	6.93e-05	2	156	2	IPR002301
Domain	Tyr_Pase_non-rcpt_typ-3/4	PTPN3 PTPN4	6.93e-05	2	156	2	IPR012151
Domain	TYR_PHOSPHATASE_1	DUSP18 PTPN3 PTPN4 PTPRD PTPRF PTPRZ1	8.36e-05	86	156	6	PS00383
Domain	TYR_PHOSPHATASE_dom	DUSP18 PTPN3 PTPN4 PTPRD PTPRF PTPRZ1	8.92e-05	87	156	6	IPR000387
Domain	TYR_PHOSPHATASE_2	DUSP18 PTPN3 PTPN4 PTPRD PTPRF PTPRZ1	8.92e-05	87	156	6	PS50056
Domain	-	DUSP18 PTPN3 PTPN4 PTPRD PTPRF PTPRZ1	1.22e-04	92	156	6	3.90.190.10
Domain	PTPc_motif	PTPN3 PTPN4 PTPRD PTPRF PTPRZ1	1.33e-04	59	156	5	SM00404
Domain	Tyr_Pase_cat	PTPN3 PTPN4 PTPRD PTPRF PTPRZ1	1.33e-04	59	156	5	IPR003595
Domain	Prot-tyrosine_phosphatase-like	DUSP18 PTPN3 PTPN4 PTPRD PTPRF PTPRZ1	1.82e-04	99	156	6	IPR029021
Domain	Dynein_heavy_chain_D4_dom	DNAH3 DNAH1 DNAH6	1.94e-04	14	156	3	IPR024317
Domain	Dynein_HC_stalk	DNAH3 DNAH1 DNAH6	1.94e-04	14	156	3	IPR024743
Domain	Dynein_heavy_dom-2	DNAH3 DNAH1 DNAH6	1.94e-04	14	156	3	IPR013602
Domain	DHC_N2	DNAH3 DNAH1 DNAH6	1.94e-04	14	156	3	PF08393
Domain	ATPase_dyneun-rel_AAA	DNAH3 DNAH1 DNAH6	1.94e-04	14	156	3	IPR011704
Domain	MT	DNAH3 DNAH1 DNAH6	1.94e-04	14	156	3	PF12777
Domain	AAA_8	DNAH3 DNAH1 DNAH6	1.94e-04	14	156	3	PF12780
Domain	AAA_5	DNAH3 DNAH1 DNAH6	1.94e-04	14	156	3	PF07728
Domain	DHC_fam	DNAH3 DNAH1 DNAH6	2.42e-04	15	156	3	IPR026983
Domain	Dynein_heavy	DNAH3 DNAH1 DNAH6	2.42e-04	15	156	3	PF03028
Domain	Dynein_heavy_dom	DNAH3 DNAH1 DNAH6	2.42e-04	15	156	3	IPR004273
Domain	Pkinase_C	RPS6KA4 RPS6KA1 RPS6KA3 RPS6KA6	2.50e-04	37	156	4	IPR017892
Domain	Pkinase_C	RPS6KA4 RPS6KA1 RPS6KA3 RPS6KA6	4.09e-04	42	156	4	PF00433
Domain	Peptidase_M1_C	RNPEP LTA4H	4.11e-04	4	156	2	IPR015211
Domain	Leuk-A4-hydro_C	RNPEP LTA4H	4.11e-04	4	156	2	SM01263
Domain	Leuk-A4-hydro_C	RNPEP LTA4H	4.11e-04	4	156	2	PF09127
Domain	aa-tRNA-synth_I_CS	WARS1 IARS1 IARS2	4.25e-04	18	156	3	IPR001412
Domain	Rossmann-like_a/b/a_fold	WARS1 IARS1 IARS2 FLAD1	4.49e-04	43	156	4	IPR014729
Domain	-	WARS1 IARS1 IARS2 FLAD1	4.49e-04	43	156	4	3.40.50.620
Domain	AA_TRNA_LIGASE_I	WARS1 IARS1 IARS2	5.02e-04	19	156	3	PS00178
Domain	-	FZD1 CORIN MUSK	6.81e-04	21	156	3	1.10.2000.10
Domain	Tyr_kinase_cat_dom	JAK3 MET MUSK EPHA4 EPHA7	8.55e-04	88	156	5	IPR020635
Domain	TyrKc	JAK3 MET MUSK EPHA4 EPHA7	8.55e-04	88	156	5	SM00219
Domain	Frizzled_dom	FZD1 CORIN MUSK	1.02e-03	24	156	3	IPR020067
Domain	FZ	FZD1 CORIN MUSK	1.02e-03	24	156	3	PS50038
Domain	Fz	FZD1 CORIN MUSK	1.02e-03	24	156	3	PF01392
Domain	Val/Leu/Ile-tRNA-synth_edit	IARS1 IARS2	1.02e-03	6	156	2	IPR009008
Domain	Anticodon_1	IARS1 IARS2	1.02e-03	6	156	2	PF08264
Domain	M/V/L/I-tRNA-synth_anticd-bd	IARS1 IARS2	1.02e-03	6	156	2	IPR013155
Domain	-	IARS1 IARS2	1.02e-03	6	156	2	3.90.740.10
Domain	AGC-kinase_C	RPS6KA4 RPS6KA1 RPS6KA3 RPS6KA6	1.23e-03	56	156	4	IPR000961
Domain	AGC_KINASE_CTER	RPS6KA4 RPS6KA1 RPS6KA3 RPS6KA6	1.23e-03	56	156	4	PS51285
Domain	S_TK_X	RPS6KA4 RPS6KA1 RPS6KA3 RPS6KA6	1.23e-03	56	156	4	SM00133
Domain	PROTEIN_KINASE_TYR	JAK3 MET MUSK EPHA4 EPHA7	1.32e-03	97	156	5	PS00109
Domain	Tyr_kinase_AS	JAK3 MET MUSK EPHA4 EPHA7	1.32e-03	97	156	5	IPR008266
Domain	aa-tRNA-synth_Ia	IARS1 IARS2	1.42e-03	7	156	2	IPR002300
Domain	tRNA-synt_1	IARS1 IARS2	1.42e-03	7	156	2	PF00133
Domain	SRCR_2	TMPRSS3 CORIN	1.42e-03	7	156	2	PF15494
Domain	fn3	PTPRD PTPRF PTPRZ1 CDON EPHA4 EPHA7	2.42e-03	162	156	6	PF00041
Domain	TPR_7	TTC28 TTC8	2.99e-03	10	156	2	PF13176
Domain	-	IARS1 IARS2	3.63e-03	11	156	2	1.10.730.10
Domain	Peptidase_M1	RNPEP LTA4H	4.33e-03	12	156	2	IPR001930
Domain	Pkinase_Tyr	JAK3 MET MUSK EPHA4 EPHA7	4.57e-03	129	156	5	PF07714
Domain	Protein_kinase_ATP_BS	RPS6KA4 RPS6KA1 RPS6KA3 JAK3 MET RPS6KA6 MUSK EPHA4 EPHA7	4.64e-03	379	156	9	IPR017441
Domain	FN3	PTPRD PTPRF PTPRZ1 CDON EPHA4 EPHA7	4.65e-03	185	156	6	SM00060
Domain	Peptidase_M1_N	RNPEP LTA4H	5.09e-03	13	156	2	IPR014782
Domain	Peptidase_M1	RNPEP LTA4H	5.09e-03	13	156	2	PF01433
Domain	PROTEIN_KINASE_ATP	RPS6KA4 RPS6KA1 RPS6KA3 LRRK1 JAK3 MET RPS6KA6 MUSK EPHA4 EPHA7	5.28e-03	459	156	10	PS00107
Domain	SAM_2	SFMBT2 EPHA4 EPHA7	5.52e-03	43	156	3	PF07647
Domain	RECEPTOR_TYR_KIN_V_2	EPHA4 EPHA7	5.91e-03	14	156	2	PS00791
Domain	RECEPTOR_TYR_KIN_V_1	EPHA4 EPHA7	5.91e-03	14	156	2	PS00790
Domain	Tyr_kinase_rcpt_V_CS	EPHA4 EPHA7	5.91e-03	14	156	2	IPR001426
Domain	EphA2_TM	EPHA4 EPHA7	5.91e-03	14	156	2	PF14575
Domain	Ephrin_rcpt_lig-bd_dom	EPHA4 EPHA7	5.91e-03	14	156	2	IPR001090
Domain	Eph_TM	EPHA4 EPHA7	5.91e-03	14	156	2	IPR027936
Domain	EPH_lbd	EPHA4 EPHA7	5.91e-03	14	156	2	SM00615
Domain	Ephrin_lbd	EPHA4 EPHA7	5.91e-03	14	156	2	PF01404
Domain	Tyr_kinase_ephrin_rcpt	EPHA4 EPHA7	5.91e-03	14	156	2	IPR016257
Domain	EPH_LBD	EPHA4 EPHA7	5.91e-03	14	156	2	PS51550
Domain	Ser-Thr/Tyr_kinase_cat_dom	JAK3 MET MUSK EPHA4 EPHA7	6.07e-03	138	156	5	IPR001245
Domain	FN3	PTPRD PTPRF PTPRZ1 CDON EPHA4 EPHA7	6.59e-03	199	156	6	PS50853
Domain	tRNAsynth_Ia_anticodon-bd	IARS1 IARS2	6.78e-03	15	156	2	IPR009080
Domain	FERM_domain	JAK3 PTPN3 PTPN4	7.95e-03	49	156	3	IPR000299
Domain	Prot_kinase_dom	RPS6KA4 RPS6KA1 RPS6KA3 LRRK1 JAK3 MET RPS6KA6 MUSK EPHA4 EPHA7	8.10e-03	489	156	10	IPR000719
Domain	FN3_dom	PTPRD PTPRF PTPRZ1 CDON EPHA4 EPHA7	8.30e-03	209	156	6	IPR003961
Pathway	REACTOME_RAS_PROCESSING	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	4.14e-15	45	128	12	MM15671
Pathway	REACTOME_UB_SPECIFIC_PROCESSING_PROTEASES	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 PSMD5 USP17L10 USP17L19 KAT2A USP17L18 USP10 USP17L17 USP17L6P USP17L22 USP17L13	1.90e-10	191	128	15	MM15289
Pathway	REACTOME_DEUBIQUITINATION	USP17L21 USP17L12 USP17L20 USP17L11 APC USP17L5 PSMD5 USP17L10 USP17L19 KAT2A USP17L18 USP10 USP17L17 OTUD7A USP17L6P USP17L22 USP17L13	2.18e-10	262	128	17	MM15286
Pathway	REACTOME_UB_SPECIFIC_PROCESSING_PROTEASES	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 PSMD5 USP17L10 USP17L19 KAT2A USP17L18 USP10 USP17L17 USP17L22 USP17L13	1.46e-09	221	128	15	M27578
Pathway	REACTOME_DEUBIQUITINATION	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 APC USP17L5 PSMD5 USP17L10 USP17L19 KAT2A USP17L18 USP10 USP17L17 OTUD7A USP17L22 USP17L13	1.67e-09	299	128	17	M27574
Pathway	REACTOME_MAPK_FAMILY_SIGNALING_CASCADES	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 PSMD5 USP17L10 USP17L19 USP17L18 MET PTPN3 USP17L17 USP17L6P USP17L22 USP17L13	1.90e-07	318	128	15	MM15278
Pathway	REACTOME_CREB1_PHOSPHORYLATION_THROUGH_NMDA_RECEPTOR_MEDIATED_ACTIVATION_OF_RAS_SIGNALING	RPS6KA1 RPS6KA3 RPS6KA6	7.22e-06	5	128	3	MM15108
Pathway	KEGG_MEDICUS_REFERENCE_ERK_RSK_SIGNALING	RPS6KA1 RPS6KA3 RPS6KA6	1.43e-05	6	128	3	M47936
Pathway	REACTOME_RSK_ACTIVATION	RPS6KA1 RPS6KA3 RPS6KA6	2.49e-05	7	128	3	M27369
Pathway	REACTOME_POST_NMDA_RECEPTOR_ACTIVATION_EVENTS	RPS6KA1 RPS6KA3 RPS6KA6	3.07e-04	15	128	3	MM15103
Pubmed	DUB-1, a deubiquitinating enzyme with growth-suppressing activity.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.55e-23	21	159	12	8622927
Pubmed	DUB-1A, a novel deubiquitinating enzyme subfamily member, is polyubiquitinated and cytokine-inducible in B-lymphocytes.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.55e-23	21	159	12	14583620
Pubmed	DUB-2A, a new member of the DUB subfamily of hematopoietic deubiquitinating enzymes.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.55e-23	21	159	12	11468161
Pubmed	The murine DUB-1 gene is specifically induced by the betac subunit of interleukin-3 receptor.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.55e-23	21	159	12	8756639
Pubmed	Lymphocyte-specific murine deubiquitinating enzymes induced by cytokines.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.55e-23	21	159	12	12447969
Pubmed	DUB-1, a fate determinant of dynein heavy chain in B-lymphocytes, is regulated by the ubiquitin-proteasome pathway.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.55e-23	21	159	12	18980247
Pubmed	JAK2 is required for induction of the murine DUB-1 gene.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	3.39e-23	22	159	12	9154835
Pubmed	Cdc25A and Dub3 in a high-stakes balancing act.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.22e-22	33	159	13	20228807
Pubmed	DUB-2 is a member of a novel family of cytokine-inducible deubiquitinating enzymes.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.41e-22	24	159	12	8995226
Pubmed	The DUB/USP17 deubiquitinating enzymes: a gene family within a tandemly repeated sequence, is also embedded within the copy number variable beta-defensin cluster.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.97e-22	34	159	13	20403174
Pubmed	DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.97e-22	34	159	13	14699124
Pubmed	The DUB/USP17 deubiquitinating enzymes, a multigene family within a tandemly repeated sequence.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.97e-22	34	159	13	15780755
Pubmed	USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.97e-22	34	159	13	19188362
Pubmed	Unstable transmission of the RS447 human megasatellite tandem repetitive sequence that contains the USP17 deubiquitinating enzyme gene.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.97e-22	34	159	13	11941478
Pubmed	Hyaluronan- and RNA-binding deubiquitinating enzymes of USP17 family members associated with cell viability.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.97e-22	34	159	13	17109758
Pubmed	The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.97e-22	34	159	13	20388806
Pubmed	Polyclonal and monoclonal antibodies specific for USP17, a proapoptotic deubiquitinating enzyme.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.97e-22	34	159	13	20715989
Pubmed	Human megasatellite DNA RS447: copy-number polymorphisms and interspecies conservation.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.97e-22	34	159	13	9806828
Pubmed	The ubiquitin-specific protease 17 is involved in virus-triggered type I IFN signaling.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.97e-22	34	159	13	20368735
Pubmed	The RS447 human megasatellite tandem repetitive sequence encodes a novel deubiquitinating enzyme with a functional promoter.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.97e-22	34	159	13	10936051
Pubmed	The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.97e-22	34	159	13	21448158
Pubmed	Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	2.70e-22	25	159	12	21115691
Pubmed	Cytokine-regulated protein degradation by the ubiquitination system.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	3.13e-22	35	159	13	16611142
Pubmed	Lys-63-specific deubiquitination of SDS3 by USP17 regulates HDAC activity.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	3.13e-22	35	159	13	21239494
Pubmed	The deubiquitinating enzyme USP17 blocks N-Ras membrane trafficking and activation but leaves K-Ras unaffected.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	4.87e-22	36	159	13	20147298
Pubmed	Decabromodiphenyl ethane affects embryonic development by interfering with nuclear F-actin in zygotes and leads to cognitive and social disorders in offspring mice.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	4.99e-22	26	159	12	35816173
Pubmed	Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	7.48e-22	37	159	13	20228808
Pubmed	Minor Splicing Factors Zrsr1 and Zrsr2 Are Essential for Early Embryo Development and 2-Cell-Like Conversion.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	2.65e-21	29	159	12	32527007
Pubmed	DUX is a non-essential synchronizer of zygotic genome activation.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	5.71e-18	50	159	12	31806660
Pubmed	USP7 represses lineage differentiation genes in mouse embryonic stem cells by both catalytic and noncatalytic activities.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 IRF2 USP17L10 USP17L19 NXT2 USP17L18 HHIP USP17L17 USP17L6P TRPM1 USP17L22 USP17L13	9.35e-08	674	159	16	37196079
Pubmed	The RSK2-RPS6 axis promotes axonal regeneration in the peripheral and central nervous systems.	RPS6KA1 RPS6KA3 RPS6KA6	9.31e-07	5	159	3	37068088
Pubmed	RSK2 is a modulator of craniofacial development.	RPS6KA1 RPS6KA3 RPS6KA6	9.31e-07	5	159	3	24416220
Pubmed	Cognitive impairment in Coffin-Lowry syndrome correlates with reduced RSK2 activation.	RPS6KA1 RPS6KA3 RPS6KA6	9.31e-07	5	159	3	11160957
Pubmed	A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.	USP17L21 USP17L12 USP17L20 USP17L11 USP17L19 USP17L18 USP17L17	1.33e-06	119	159	7	28625976
Pubmed	Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity.	RPS6KA1 RPS6KA3 RPS6KA6	1.86e-06	6	159	3	12832467
Pubmed	Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase.	RPS6KA4 RPS6KA1 RPS6KA3	1.86e-06	6	159	3	8688081
Pubmed	NO activation of fos promoter elements requires nuclear translocation of G-kinase I and CREB phosphorylation but is independent of MAP kinase activation.	RPS6KA4 RPS6KA1 RPS6KA3	1.86e-06	6	159	3	11175347
Pubmed	Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.	VAPB RPS6KA4 RPS6KA1 RPS6KA3 MET PTPRD PTPRF TIMM50 RPS6KA6	3.00e-06	256	159	9	24189400
Pubmed	CREB is a regulatory target for the protein kinase Akt/PKB.	RPS6KA4 RPS6KA1 RPS6KA3	5.16e-06	8	159	3	9829964
Pubmed	Differential control of Toll-like receptor 4-induced interleukin-10 induction in macrophages and B cells reveals a role for p90 ribosomal S6 kinases.	RPS6KA4 RPS6KA1 RPS6KA3	1.10e-05	10	159	3	29229781
Pubmed	Isoleucylation properties of native human mitochondrial tRNAIle and tRNAIle transcripts. Implications for cardiomyopathy-related point mutations (4269, 4317) in the tRNAIle gene.	IARS1 IARS2	2.08e-05	2	159	2	9466989
Pubmed	Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells.	CD226 PVR	2.08e-05	2	159	2	32040157
Pubmed	Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells.	CD226 PVR	2.08e-05	2	159	2	19801517
Pubmed	Receptor-type protein tyrosine phosphatase beta (RPTP-beta) directly dephosphorylates and regulates hepatocyte growth factor receptor (HGFR/Met) function.	MET PTPRZ1	2.08e-05	2	159	2	21454675
Pubmed	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.	CD226 PVR	2.08e-05	2	159	2	33053330
Pubmed	Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway.	MET CD82	2.08e-05	2	159	2	18272501
Pubmed	The CD226/CD155 interaction regulates the proinflammatory (Th1/Th17)/anti-inflammatory (Th2) balance in humans.	CD226 PVR	2.08e-05	2	159	2	23980210
Pubmed	Liver receptor homolog 1 contributes to intestinal tumor formation through effects on cell cycle and inflammation.	APC NR5A2	2.08e-05	2	159	2	15684064
Pubmed	Heterogeneous expression of the adhesion receptor CD226 on murine NK and T cells and its function in NK-mediated killing of immature dendritic cells.	CD226 PVR	2.08e-05	2	159	2	19380711
Pubmed	RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells.	RPS6KA1 RPS6KA3	2.08e-05	2	159	2	19716794
Pubmed	The RSK family of kinases: emerging roles in cellular signalling.	RPS6KA1 RPS6KA3	2.08e-05	2	159	2	18813292
Pubmed	Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism.	RPS6KA1 RPS6KA3	2.08e-05	2	159	2	26625210
Pubmed	RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.	MET PTPRZ1	2.08e-05	2	159	2	25135958
Pubmed	Expression and possible role of PVR/CD155/Necl-5 in osteoclastogenesis.	CD226 PVR	2.08e-05	2	159	2	17286202
Pubmed	The mouse gene Ptprf encoding the leukocyte common antigen-related molecule LAR: cloning, characterization, and chromosomal localization.	PTPRD PTPRF	2.08e-05	2	159	2	7665159
Pubmed	Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells.	CD226 PVR	2.08e-05	2	159	2	38289706
Pubmed	A viral microRNA downregulates metastasis suppressor CD82 and induces cell invasion and angiogenesis by activating the c-Met signaling.	MET CD82	2.08e-05	2	159	2	28534512
Pubmed	S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover.	RPS6KA1 RPS6KA3	2.08e-05	2	159	2	17494629
Pubmed	Upregulation of the CD155-CD226 Axis Is Associated With Muscle Inflammation and Disease Severity in Idiopathic Inflammatory Myopathies.	CD226 PVR	2.08e-05	2	159	2	37491355
Pubmed	PSMD5 Inactivation Promotes 26S Proteasome Assembly during Colorectal Tumor Progression.	APC PSMD5	2.08e-05	2	159	2	29716915
Pubmed	Sonic Hedgehog promotes tumor cell survival by inhibiting CDON pro-apoptotic activity.	APC CDON	2.08e-05	2	159	2	23940460
Pubmed	UPR decreases CD226 ligand CD155 expression and sensitivity to NK cell-mediated cytotoxicity in hepatoma cells.	CD226 PVR	2.08e-05	2	159	2	25209846
Pubmed	High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation.	MET PTPRZ1	2.08e-05	2	159	2	33645009
Pubmed	Over-expression of a novel member of the immunoglobulin superfamily in Min mouse intestinal adenomas.	APC PVR	2.08e-05	2	159	2	8980189
Pubmed	CD155/CD226-interaction impacts on the generation of innate CD8(+) thymocytes by regulating iNKT-cell differentiation.	CD226 PVR	2.08e-05	2	159	2	26689152
Pubmed	Phospholipase Cgamma activation drives increased production of autotaxin in endothelial cells and lysophosphatidic acid-dependent regression.	ENPP2 PLCG1	2.08e-05	2	159	2	20231358
Pubmed	Genetic deletion or tyrosine phosphatase inhibition of PTPRZ1 activates c-Met to up-regulate angiogenesis and lung adenocarcinoma growth.	MET PTPRZ1	2.08e-05	2	159	2	37260355
Pubmed	Selective DNAM-1 expression on small peritoneal macrophages contributes to CD4+ T cell costimulation.	CD226 PVR	2.08e-05	2	159	2	30315271
Pubmed	DNAM-1 and PVR regulate monocyte migration through endothelial junctions.	CD226 PVR	2.08e-05	2	159	2	15136589
Pubmed	Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions.	MET PTPRZ1	2.08e-05	2	159	2	25935522
Pubmed	Expression of JAK3 Sensitive Na+ Coupled Glucose Carrier SGLT1 in Activated Cytotoxic T Lymphocytes.	SLC5A1 JAK3	2.08e-05	2	159	2	27595398
Pubmed	Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.	RPS6KA1 RPS6KA3	2.08e-05	2	159	2	25889895
Pubmed	Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5.	CD226 PVR	2.08e-05	2	159	2	30591568
Pubmed	Comprehensive analysis of the RSK gene family in acute myeloid leukemia determines a prognostic signature for the prediction of clinical prognosis and treatment responses.	RPS6KA4 RPS6KA1	2.08e-05	2	159	2	37462338
Pubmed	Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.	MET PTPRZ1	2.08e-05	2	159	2	28504721
Pubmed	EphA4 has distinct functionality from EphA7 in the corticothalamic system during mouse brain development.	EPHA4 EPHA7	2.08e-05	2	159	2	26587807
Pubmed	NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions.	CD226 PVR	2.08e-05	2	159	2	26588911
Pubmed	Structural basis for the recognition of nectin-like protein-5 by the human-activating immune receptor, DNAM-1.	CD226 PVR	2.08e-05	2	159	2	31253644
Pubmed	Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.	CD226 PVR	2.08e-05	2	159	2	25609078
Pubmed	The DNA repair endonuclease XPG interacts directly and functionally with the WRN helicase defective in Werner syndrome.	ERCC5 WRN	2.08e-05	2	159	2	21558802
Pubmed	Sequence and expression of chicken and mouse rsk: homologs of Xenopus laevis ribosomal S6 kinase.	RPS6KA1 RPS6KA3	2.08e-05	2	159	2	2779569
Pubmed	A case of pediatric acute myeloid leukemia with t(11;16)(q23;q24) leading to a novel KMT2A-USP10 fusion gene.	USP10 KMT2A	2.08e-05	2	159	2	30107050
Pubmed	CD226 interaction with CD155 impacts on retention and negative selection of CD8 positive thymocytes as well as T cell differentiation to follicular helper cells in Peyer's Patches.	CD226 PVR	2.08e-05	2	159	2	22429743
Pubmed	Combinatorial CRISPR screen identifies fitness effects of gene paralogues.	PARG KAT2A MET KMT2A SLC25A28 DAGLA SEC23B	2.51e-05	186	159	7	33637726
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	ATRN ATP6V1B2 DCAF6 WARS1 TTC28 COPB1 ENPP2 ZNF423 GNPTAB APC PSMD5 MAPK8IP3 PTPRD PCMTD2 PLCG1 ZNF439 MED13 RECK	2.59e-05	1285	159	18	35914814
Pubmed	The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes.	APC KAT2A KMT2A	2.59e-05	13	159	3	16510874
Pubmed	Ephrin-A3 is required for tonotopic map precision and auditory functions in the mouse auditory brainstem.	CHAT EPHA4 EPHA7	3.29e-05	14	159	3	34235739
Pubmed	Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB.	RPS6KA4 RPS6KA1 RPS6KA3	3.29e-05	14	159	3	9687510
Pubmed	Identification of dynein heavy chain genes expressed in human and mouse testis: chromosomal localization of an axonemal dynein gene.	DNAH3 DNAH1 DNAH6	3.29e-05	14	159	3	9373155
Pubmed	Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients.	PTPRD CNTNAP4 EPHA4	3.29e-05	14	159	3	24811271
Pubmed	Genome wide association study (GWAS) of Chagas cardiomyopathy in Trypanosoma cruzi seropositive subjects.	ABCA12 RGS6 PTPRD OTUD7A PLA2G4F PHACTR1	3.68e-05	134	159	6	24324551
Pubmed	The protein tyrosine kinase family of the human genome.	JAK3 MET MUSK EPHA4 EPHA7	4.08e-05	83	159	5	11114734
Pubmed	Cloning and characterization of PTP-K1, a novel nonreceptor protein tyrosine phosphatase highly expressed in bone marrow.	PTPN3 PTPN4 PTPRF	5.03e-05	16	159	3	8875997
Pubmed	Mapping of five subtype genes for muscarinic acetylcholine receptor to mouse chromosomes.	CHRM2 MET CD82	6.08e-05	17	159	3	10549128
Pubmed	Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients.	CD226 PVR	6.21e-05	3	159	2	21383766
Pubmed	SH3P2 is a negative regulator of cell motility whose function is inhibited by ribosomal S6 kinase-mediated phosphorylation.	RPS6KA1 RPS6KA3	6.21e-05	3	159	2	21501342
Pubmed	p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling.	RPS6KA1 RPS6KA3	6.21e-05	3	159	2	19332537
Pubmed	p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors.	RPS6KA1 RPS6KA3	6.21e-05	3	159	2	36612117
Pubmed	Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.	RPS6KA1 RPS6KA3	6.21e-05	3	159	2	19036157
Pubmed	A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.	MET PLCG1	6.21e-05	3	159	2	7513258
Interaction	RYK interactions	NCKAP1 PCDHGA7 MET KIDINS220 PTPRD PTPRF PVR TIMM50 CDON EPHA4 EPHA7	8.27e-07	212	156	11	int:RYK
Cytoband	4p16.1	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.25e-18	79	158	13	4p16.1
Cytoband	Ensembl 112 genes in cytogenetic band chr4p16	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.11e-12	222	158	13	chr4p16
GeneFamily	Mitogen-activated protein kinase-activated protein kinases	RPS6KA4 RPS6KA1 RPS6KA3 RPS6KA6	2.71e-07	11	99	4	1156
GeneFamily	Fibronectin type III domain containing	PTPRD PTPRF PTPRZ1 ELFN1 CDON EPHA4 EPHA7	2.80e-05	160	99	7	555
GeneFamily	Dyneins, axonemal	DNAH3 DNAH1 DNAH6	1.02e-04	17	99	3	536
GeneFamily	Aminoacyl tRNA synthetases, Class I	WARS1 IARS1 IARS2	1.45e-04	19	99	3	131
GeneFamily	Protein tyrosine phosphatases, receptor type	PTPRD PTPRF PTPRZ1	1.97e-04	21	99	3	813
GeneFamily	Fibronectin type III domain containing\|Sterile alpha motif domain containing\|EPH receptors	EPHA4 EPHA7	2.59e-03	14	99	2	1095
Coexpression	MADAN_DPPA4_TARGETS	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.45e-13	86	157	12	MM1312
Coexpression	GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 PVR USP17L6P USP17L22 USP17L13	1.57e-13	112	157	13	MM1095
Coexpression	GERY_CEBP_TARGETS	USP17L21 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	2.51e-10	160	157	12	MM1155
Coexpression	GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP	USP17L21 ERCC5 MAN2B1 USP17L12 USP17L20 USP17L11 USP17L5 USP17L10 USP17L19 USP17L18 RNPEP USP17L17 USP17L6P USP17L22 PADI1 USP17L13	1.87e-06	647	157	16	MM981
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	LRRK1 MET PTPN3 RGS6 PTPRD OTOGL DNAH6 EPHA4 PHACTR1	1.80e-08	188	152	9	50c1b1d690f0e9443082f2adf4f1b8e9ce4cd337
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABCA12 KIF26B FIGN DNAH1 PTPRD OTOGL CNTNAP4 EPHA7	2.38e-07	184	152	8	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABCA12 KIF26B FIGN DNAH1 PTPRD OTOGL CNTNAP4 EPHA7	2.38e-07	184	152	8	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ABCA12 KIF26B FIGN DNAH1 PTPRD OTOGL CNTNAP4 EPHA7	2.38e-07	184	152	8	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	DCAF6 LRRK1 PTPN3 RGS6 PTPRD OTOGL EPHA4 PHACTR1	2.70e-07	187	152	8	f18628ffc7ff7c762b8339ba8822cf0c3157f469
ToppCell	NS-moderate-d_16-33-Epithelial-Secretory\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	NCKAP1 LAPTM4B CFB MET PTPN3 LSR PTPRZ1 ADGRF1	3.86e-07	196	152	8	70384c1da9baed843f414cfd1403ddd586a2db07
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_5-Exc_L4-5_RORB_LINC01474\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	GRM3 MET PTPN3 FSHR CNTNAP4 KCNAB1 EPHA4	2.69e-06	178	152	7	5522b179c2e7dd707de01e2df10556349d0382a6
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_2\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	LRRK1 CHRM2 PTPRD OTOGL PTPRZ1 FSHR EPHA4	2.79e-06	179	152	7	8766a5a066091879f521acfc612abf563ff78808
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	LRRK1 RGS6 PTPRD OTOGL DNAH6 EPHA4 PHACTR1	3.12e-06	182	152	7	14a117c5e50db31ee1b2cf4df4d133451fd6d55f
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	TTC28 KIF26B FIGN MET PTPRD UGT2A3 EPHA7	4.00e-06	189	152	7	3b48b0d220cc24d5170713d61fa91f5bb6c21841
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	CPAMD8 VEPH1 MET PTPN3 HHIP PTPRD EPHA7	4.28e-06	191	152	7	34cc997e4e5c727495f321e6807a84aa124da486
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TTC28 KIF26B FIGN MET PTPRD UGT2A3 EPHA7	4.28e-06	191	152	7	1cb02007adb344f17ef73d58890f91298c7cf5a1
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	VEPH1 MET PTPN3 HHIP PTPRD PLA2G4F PHACTR1	4.43e-06	192	152	7	fb2f0e897228f808d9ff734ad05e9b49dc38fa50
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-C\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ENPP2 GRM3 HHIP PTPRD CLCN4 OTUD7A CNTNAP4	4.43e-06	192	152	7	3ce5dbde41aeb73d49f2c7991d34682f0827fa5a
ToppCell	CV-Severe-6\|CV / Virus stimulation, Condition and Cluster	WARS1 RPS6KA1 GNPTAB IRF2 SIT1 CD38 TMPRSS3	4.91e-06	195	152	7	69095c6ce2a7e763afa543c10d5710e0c3dda769
ToppCell	moderate-Epithelial-Secretory\|moderate / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	NCKAP1 LAPTM4B CFB MET PTPN3 LSR ADGRF1	5.42e-06	198	152	7	7d96d7105a849c7280ce87bd76ce130ac47384fd
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ENPP2 GRM3 HHIP PTPRD CLCN4 OTUD7A CNTNAP4	5.61e-06	199	152	7	214a6a267e77e5508867b9eb48c4fbc7855ed0a0
ToppCell	Neuronal-Excitatory-eC(RORB)\|Neuronal / cells hierarchy compared to all cells using T-Statistic	LRRK1 GRM3 MET PTPRD OTOGL FSHR EPHA4	5.79e-06	200	152	7	8c803a0ce25e140b46036f6aabefc5502601f408
ToppCell	Striatum-Macroglia-ASTROCYTE-Gja1-Astrocyte.Gja1.Notum_(Notum)--\|Striatum / BrainAtlas - Mouse McCarroll V32	VEPH1 ISM2 TRPM1 PLA2G4F PADI1	8.58e-06	81	152	5	c9145c994abcf49e5492270b18b0580a3d771ccf
ToppCell	Striatum-Macroglia-ASTROCYTE-Gja1-Astrocyte.Gja1.Notum_(Notum)-\|Striatum / BrainAtlas - Mouse McCarroll V32	VEPH1 ISM2 TRPM1 PLA2G4F PADI1	8.58e-06	81	152	5	34d2a2c30c749bd2ad447dfb1e43444953d9b154
ToppCell	Striatum-Macroglia-ASTROCYTE-Gja1-Astrocyte.Gja1.Notum_(Notum)\|Striatum / BrainAtlas - Mouse McCarroll V32	VEPH1 ISM2 TRPM1 PLA2G4F PADI1	8.58e-06	81	152	5	f84bfa55c6b9548f8829b16a145690d207a7bfc1
ToppCell	LPS-IL1RA+antiTNF-Epithelial_airway-Ciliated_cells\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DNAH3 DNAH1 PTPRZ1 ADGRF1 DNAH6 LRRC71	1.55e-05	155	152	6	5f1e2195a6b831e1b636f5cc3a282ca423721822
ToppCell	LPS-IL1RA+antiTNF-Epithelial_airway-Ciliated_cells-Ciliated\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DNAH3 DNAH1 PTPRZ1 ADGRF1 DNAH6 LRRC71	1.55e-05	155	152	6	0944429459f642a1bcc56edc1ec28aaecde3e2dc
ToppCell	frontal_cortex-Neuronal-glutamatergic_neuron-L5_IT-L5_IT_ALM_Cbln4_Fezf2\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ENPP2 SSTR3 FIGN GRM3 MET EPHA4	1.86e-05	160	152	6	d8241404d775f9a709abdf17988f36293fcf4c58
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L2/3_IT\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	DUSP18 ENPP2 STRIP2 RGS6 AGMAT ALDH3B1	1.93e-05	161	152	6	e3327c296d48e821004e61a573abb75624a6f040
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_2-Exc_L3-4_RORB_SEMA6D\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	LRRK1 GRM3 MET PTPN3 OTOGL FSHR	2.53e-05	169	152	6	319cba07263bf41fcbcbfecd117f91b729394241
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_2\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	LRRK1 GRM3 MET PTPRD OTOGL EPHA4	2.62e-05	170	152	6	3174ea9cf93892a8b41de10fd4ff6f06bb41502d
ToppCell	facs-Heart-RA-18m-Mesenchymal-smooth_muscle_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCLY GRM3 RGS6 PTPRF KCNAB1 CORIN	2.71e-05	171	152	6	b54d9d6b03c9c6f28a71cf2ed2bfa9a335bba949
ToppCell	facs-Heart-RA-18m-Mesenchymal-smooth_muscle_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCLY GRM3 RGS6 PTPRF KCNAB1 CORIN	2.71e-05	171	152	6	9d825a2e799421af4f2cf4f4dc8e239b5d00476d
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_2-Exc_L3-4_RORB_SEMA6D\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	LRRK1 GRM3 MET PTPN3 OTOGL FSHR	2.89e-05	173	152	6	9a2d42f8d9cb834856522661d524abb91c4637c5
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_2\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	LRRK1 GRM3 MET PTPRD OTOGL EPHA4	2.98e-05	174	152	6	b3cd22e717d178269e6d5bd5ed7b2d945cd8ea25
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_2-Exc_L3-4_RORB_PRSS12\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	LRRK1 CHRM2 MET OTOGL PTPRZ1 FSHR	3.28e-05	177	152	6	f902600c639087664316b3cf30cab243bc3d1c5c
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	FIGN SLC5A1 MET PTPRD UGT2A3 EPHA7	3.50e-05	179	152	6	58ae5a97fe2a14e1c6fdeb886397eb06fdaf0428
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_5\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	LRRK1 GRM3 MET FSHR CNTNAP4 EPHA4	3.72e-05	181	152	6	6e8c5460021d3999daec58e3d6661a6fa998fd16
ToppCell	facs-Liver-Hepatocytes-24m\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ENPP2 NXT2 CFB PTPRD PTPRF GPT2	3.95e-05	183	152	6	d0721c6aa426953a520d40e976b6e65aa7ca65e8
ToppCell	E15.5-Mesenchymal-mesenchymal_fibroblast-mesothelial_cell_of_visceral_pleura\|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	ENPP2 CHRM2 HHIP CD82 RGS6 KCNAB1	3.95e-05	183	152	6	274f274cf60daa30d6a4cd603a3af7823bfb8016
ToppCell	COVID-19-Epithelial_cells-AT2\|COVID-19 / group, cell type (main and fine annotations)	VEPH1 MET HHIP PLA2G4F ADGRF1 PHACTR1	4.08e-05	184	152	6	369b82f793deab672204558ae4e112cfa5aa9ccc
ToppCell	Control-Epithelial_cells-Airway_goblet\|Control / group, cell type (main and fine annotations)	MET RGS6 MUC17 TMPRSS3 ADGRF1 PADI1	4.08e-05	184	152	6	d92a71441e4e19f8c301999d8186f8e48e3cd162
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c02-AQP3\|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)	TTC28 LSR CD82 RPS6KA6 SENP7 EPHA4	4.20e-05	185	152	6	e34473eea3a58c041183a4f52137366cd9489495
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_adventitial_fibro_(9)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	KIF26B CHRM2 FZD1 RGS6 PTPRD CDON	4.33e-05	186	152	6	8915436d09775f2828a7678af203b1082b36e21c
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_mesothelial_(19)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	CHRM2 HHIP RGS6 OTOGL CDON PHACTR1	4.46e-05	187	152	6	8e8f1f2a78ac5f13a414fd448af7d7ff1ea86f0f
ToppCell	368C-Epithelial_cells\|368C / Donor, Lineage, Cell class and subclass (all cells)	VEPH1 MET HHIP LSR PLA2G4F ADGRF1	4.87e-05	190	152	6	459811e88d3001816c2d89034e0921c24918c17f
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2\|Children_(3_yrs) / Lineage, Cell type, age group and donor	VEPH1 MET HHIP PTPRD PLA2G4F PHACTR1	5.02e-05	191	152	6	a0332a4ef629510fb313ec119195c44a3f704a80
ToppCell	COVID-19-lung-AT2\|lung / Disease (COVID-19 only), tissue and cell type	VEPH1 MET PTPN3 HHIP PLA2G4F ADGRF1	5.02e-05	191	152	6	276455a64c2c3503d5048615762eb2ee37f0ac70
ToppCell	droplet-Kidney-nan-3m-Epithelial-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LAPTM4B SLC5A1 CD82 KIDINS220 ELFN1 RPS6KA6	5.02e-05	191	152	6	297bc79adc5fef211497819b4861b52cd26ac754
ToppCell	droplet-Kidney-nan-3m-Epithelial-Epcam____thick_ascending_tube_S_epithelial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LAPTM4B SLC5A1 CD82 KIDINS220 ELFN1 RPS6KA6	5.02e-05	191	152	6	e1ec165ba6578cefd88895e7e183190e79f733a4
ToppCell	human_hepatoblastoma-Tumor_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	ATRN TTC28 ENPP2 RPS6KA3 WRN MED13	5.17e-05	192	152	6	916fbec1c7ab7969bda711886ac88e877e30c280
ToppCell	Healthy_Control-Lymphoid-T-CCR7+_T\|Healthy_Control / Condition, Lineage, Cell class and cell subclass	SIT1 JAK3 PTPN4 CD226 RHOF EPHA4	5.17e-05	192	152	6	5b197f65a87c315e4f50c77a7fdec3b342a863ad
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-Z\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ENPP2 GRM3 HHIP PTPRD CLCN4 CNTNAP4	5.17e-05	192	152	6	8dc3016601148243196e925641c9507e9d58c9e0
ToppCell	control-Lymphoid-CTL\|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	RPS6KA3 GNPTAB SFMBT2 CD226 KMT2A PLCG1	5.32e-05	193	152	6	89d407a88b5956559a589425b89b3eb8dc78e1dd
ToppCell	LPS-IL1RA+antiTNF-Endothelial-Endothelial-Gen_Cap\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP2 ZNF423 SFMBT2 RGS6 NR5A2 PHACTR1	5.32e-05	193	152	6	e09387af84d2a0a526e54d4793e6e06c6739db53
ToppCell	LPS-antiTNF-Endothelial-Endothelial-Gen_Cap\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ENPP2 ZNF423 SFMBT2 RGS6 NR5A2 PHACTR1	5.32e-05	193	152	6	6e1982d089a9de628e6006d23ff78a223fbd9f47
ToppCell	NS-moderate-d_0-4\|moderate / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	TMEM67 DNAH3 PTPRF PTPRZ1 BEST4 DNAH6	5.32e-05	193	152	6	ea345d34440b25f65358a53dc72831998d1c3620
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-E\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ENPP2 GRM3 HHIP PTPRD CLCN4 CNTNAP4	5.47e-05	194	152	6	cb0422e7607dbd77204428b7e2c70dfe14a6ca11
ToppCell	CD8+_Memory_T_cell-CV-6\|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster	WARS1 RPS6KA1 IRF2 CD82 CD226 CD38	5.47e-05	194	152	6	35a347c3824757b9de8b7f49db46e73e7fb63a4f
ToppCell	facs-Brain_Non-Myeloid-Striatum-3m\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATRN ENPP2 SH2D5 PTPRD CLCN4 PHACTR1	5.47e-05	194	152	6	ba529c051f248d29f4222f4bc9801ba233859093
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CPAMD8 PIEZO1 VEPH1 PTPRF ADGRF1 PHACTR1	5.47e-05	194	152	6	04bfc555743f7d8821439d05ae442d15e9886c59
ToppCell	droplet-Lung-3m-Mesenchymal-myofibroblast\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ENPP2 CHRM2 HHIP RGS6 CORIN RECK	5.47e-05	194	152	6	c992e3357f4bf3069f8d697803e5785e49a2ef0a
ToppCell	RA-03._Atrial_Cardiomyocyte\|World / Chamber and Cluster_Paper	CHRM2 RGS6 OTOGL EPHA4 EPHA7 PHACTR1	5.47e-05	194	152	6	89812fb164065041357bb37a3c2d87028ec3de4e
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	VEPH1 MET HHIP PTPRD PLA2G4F PHACTR1	5.47e-05	194	152	6	97534c8bba895a7913665e03ae4e5c4a6ad71daf
ToppCell	IPF-Endothelial-VE_Peribronchial\|IPF / Disease state, Lineage and Cell class	NCKAP1 ENPP2 ZNF423 ITGA10 NR5A2 EPHA4	5.63e-05	195	152	6	2c3ad3cb79f11119ac69c413a938d21199145040
ToppCell	356C-Epithelial_cells-Epithelial-A_(AT2)\|356C / Donor, Lineage, Cell class and subclass (all cells)	LAPTM4B VEPH1 MET HHIP PTPRF PLA2G4F	5.79e-05	196	152	6	93a5d9b8bcff7d07596ef1f4f2b74f043835fc69
ToppCell	356C-Epithelial_cells-Epithelial-A_(AT2)-\|356C / Donor, Lineage, Cell class and subclass (all cells)	LAPTM4B VEPH1 MET HHIP PTPRF PLA2G4F	5.79e-05	196	152	6	4715f19f844e7244fc4bc446cba7c8088c600fc3
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-B\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ENPP2 GRM3 HHIP PTPRD CLCN4 CNTNAP4	5.96e-05	197	152	6	82b8e22317cad6d3786bd70d91107007c0ccd7cd
ToppCell	Control_saline-Epithelial_alveolar-AT_2\|Control_saline / Treatment groups by lineage, cell group, cell type	LAPTM4B VEPH1 MET HHIP PTPRF LTA4H	5.96e-05	197	152	6	b8f62fcd6eb8f47b3cc41f616126f82c68a36e87
ToppCell	(08)_Brush+PNEC-(0)_Reference\|(08)_Brush+PNEC / shred by cell type by condition	ATRN PKD1L1 KAT2A CD82 RNPEP LTA4H	5.96e-05	197	152	6	d500bfed2a76f7300f2f17b60962c18a40efd084
ToppCell	Control_saline-Epithelial_alveolar-AT_2-AT2\|Control_saline / Treatment groups by lineage, cell group, cell type	LAPTM4B VEPH1 MET HHIP PTPRF LTA4H	5.96e-05	197	152	6	f870a26f322668781e3d2832c5d9ef2c7c91011f
ToppCell	AT2_cells-HP_01\|World / lung cells shred on cell class, cell subclass, sample id	LAPTM4B HHIP LSR PTPRF CD38 ADGRF1	5.96e-05	197	152	6	8b5d4e1c33a57c899c51feb9a6f347232f8910a3
ToppCell	COVID-CD4-exh_CD4\|COVID / Condition, Cell_class and T cell subcluster	SIT1 JAK3 CD82 CD226 RHOF SENP7	5.96e-05	197	152	6	39ee4b93625c994813044d8dd8854fba2bd99940
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-G\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ENPP2 GRM3 HHIP PTPRD CLCN4 CNTNAP4	6.13e-05	198	152	6	bdabdb11217ea16e5863aa6bfb0f04d48b17f81e
ToppCell	BAL-Severe-Epithelial-Epithelial-AT1/AT2-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NCKAP1 VEPH1 MET HHIP LSR PLA2G4F	6.13e-05	198	152	6	691a2f1779225e5519155460eeb6a2aac5f67a92
ToppCell	LPS_only-Epithelial_alveolar-AT_2-AT2\|LPS_only / Treatment groups by lineage, cell group, cell type	LAPTM4B MET HHIP PTPRF LTA4H SEC23B	6.13e-05	198	152	6	6b6572deeca98ccb015f2aa3c5ce27de44445f74
ToppCell	Parenchymal-NucSeq-Epithelial-Epi_alveolar-AT2\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	VEPH1 MET HHIP PTPRD PLA2G4F PHACTR1	6.13e-05	198	152	6	2e2a4e1756bba6f4fbe529559a97d2993c890b4b
ToppCell	IPF-Endothelial-VE_Peribronchial\|Endothelial / Disease state, Lineage and Cell class	ENPP2 LAPTM4B SFMBT2 MET NR5A2 EPHA4	6.13e-05	198	152	6	b8bd1ba268480f54451648e01631b615a3401144
ToppCell	LPS_anti-TNF-Epithelial_alveolar\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	VEPH1 MET HHIP LSR PTPRF LTA4H	6.13e-05	198	152	6	53e9ed1b19cb26be58da0f37057caca0cdfaabeb
ToppCell	facs-Brain_Non-Myeloid-Striatum-3m-Macroglial\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATRN ENPP2 GRM3 HHIP CD82 PTPRD	6.13e-05	198	152	6	27f0654fb0857e93f030e1a4b1c307b31576bbcd
ToppCell	BAL-Severe-Epithelial-Epithelial-AT1/AT2\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NCKAP1 VEPH1 MET HHIP LSR PLA2G4F	6.13e-05	198	152	6	aed0476248e9637897eefb1623ec4035f2dacd82
ToppCell	BAL-Severe-Epithelial-Epithelial-AT1/AT2\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	NCKAP1 VEPH1 MET HHIP LSR PLA2G4F	6.13e-05	198	152	6	e115eea04012e9e492e923ed080e1723c38d14fd
ToppCell	BAL-Severe-Epithelial-Epithelial-AT1/AT2-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	NCKAP1 VEPH1 MET HHIP LSR PLA2G4F	6.13e-05	198	152	6	33d1e0b6f57663544bee0ffdde83a65da764d44c
ToppCell	Severe_COVID-19-Epithelial-AT1/AT2\|Severe_COVID-19 / Disease group,lineage and cell class （2021.01.30）	NCKAP1 VEPH1 MET HHIP LSR PLA2G4F	6.13e-05	198	152	6	43e33d28d9de5033bd00d39be953542a225236ed
ToppCell	LPS_IL1RA-Epithelial_alveolar\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	VEPH1 MET HHIP LSR PTPRF LTA4H	6.30e-05	199	152	6	5b140ac88ebc25ce397ae577e48f3e271faf46e7
ToppCell	Lung_Parenchyma-Control-Epithelial\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	VEPH1 MET HHIP LSR PTPRF PLA2G4F	6.48e-05	200	152	6	c2bde99b3bc7a8740441c1a0c1394892b940b857
ToppCell	Severe-Epithelial-Epithelial-\|Severe / Condition, Lineage, Cell class and cell subclass	NCKAP1 MET PTPN3 LSR PTPRF ADGRF1	6.48e-05	200	152	6	8669ce08f93eefb8ac970e30cdc4b1f908023c54
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ENPP2 GRM3 HHIP PTPRD CLCN4 CNTNAP4	6.48e-05	200	152	6	acdef0b9096c774040948fc75621ff2b08ea2ee8
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW16-Neuroepithelial\|GW16 / Sample Type, Dataset, Time_group, and Cell type.	RPS6KA1 PIEZO1 SLC12A4 SLFN11 ALDH3B1 PHACTR1	6.48e-05	200	152	6	25f4c051c2e869481f33c22ad54de97efac444ad
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ENPP2 GRM3 HHIP PTPRD CLCN4 CNTNAP4	6.48e-05	200	152	6	091a18d6efed81cab99955c3047f172170f70476
ToppCell	Lung_Parenchyma-Control-Epithelial-Epithelial\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	VEPH1 MET HHIP LSR PTPRF PLA2G4F	6.48e-05	200	152	6	3ff9abd5e07780a59d5571da906fa15f00a1d5c2
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Oligodendrocyte\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ENPP2 GRM3 HHIP PTPRD CLCN4 CNTNAP4	6.48e-05	200	152	6	3b8513defe25262ab4b492345b2628570eaefd17
ToppCell	Severe-Epithelial\|Severe / Condition, Lineage, Cell class and cell subclass	NCKAP1 MET PTPN3 LSR PTPRF ADGRF1	6.48e-05	200	152	6	6ead9db88568bb829d564a6d8e85f71fd765bac0
ToppCell	Parenchymal-10x3prime_v2-Epithelial-Epi_submucosal-gland-SMG_Duct\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	VEPH1 CFB SLC5A1 MET ADGRF1 DAGLA	6.48e-05	200	152	6	1b527bebbca1ef8c52449e40beb9358e37494e04
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ENPP2 GRM3 HHIP PTPRD CLCN4 CNTNAP4	6.48e-05	200	152	6	0bfd41c12887479ceb62c3db0a3c3ba5007eb62b
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ENPP2 GRM3 HHIP PTPRD CLCN4 CNTNAP4	6.48e-05	200	152	6	159377d904394d91e09913131e9a93e08189955a
ToppCell	10x_3'_v2v3-Non-neoplastic-Glial-Neuronal\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	ENPP2 GRM3 HHIP PTPRD CLCN4 CNTNAP4	6.48e-05	200	152	6	d30316836494f33ca46d4e415fd2ed179e9cb5ee
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW16-Neuroepithelial-Proteoglycan-expressing_cell\|GW16 / Sample Type, Dataset, Time_group, and Cell type.	RPS6KA1 PIEZO1 SLC12A4 SLFN11 ALDH3B1 PHACTR1	6.48e-05	200	152	6	da45a85a4667965b24ba824af871157af5b4cd19
ToppCell	Parenchymal-10x5prime-Epithelial\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	VEPH1 MET HHIP LSR PTPRF PLA2G4F	6.48e-05	200	152	6	4e5b6cb014d9bcb58e13c7511c86c43e27c496e4
ToppCell	Parenchyma_Control_(B.)-Epithelial-TX\|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type	VEPH1 MET HHIP LSR PTPRF PLA2G4F	6.48e-05	200	152	6	9970e9bde6aa2ff3aef60dcb065ff15b7463e147
ToppCell	Severe-Epithelial-Epithelial\|Severe / Condition, Lineage, Cell class and cell subclass	NCKAP1 MET PTPN3 LSR PTPRF ADGRF1	6.48e-05	200	152	6	3bd1ce2793651c9badd69f011d2531183594e5f4
ToppCell	COVID-19_Severe-dn_T\|COVID-19_Severe / Disease condition and Cell class	SIT1 MET PTPN3 CD38 ERICH6	1.27e-04	142	152	5	2008033881b9e1b20926c3508d6ebdb6f1a1528f
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Lmo1_Myl1\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	PIPOX CHAT FZD1 PTPRZ1 ELFN1	1.36e-04	144	152	5	0322fef818a963be00535d5f141f028d43de5c6a
ToppCell	frontal_cortex-Neuronal-glutamatergic_neuron-L2/3_IT\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	DUSP18 ENPP2 STRIP2 AGMAT ALDH3B1	1.54e-04	148	152	5	d5cace5605bff2bb8248fadb51f2dad7539930ba
Drug	Ovta	RPS6KA4 RPS6KA1 RPS6KA3 RPS6KA6	1.59e-06	14	147	4	CID003081047
Drug	AD 288	RPS6KA4 RPS6KA1 RPS6KA3 RPS6KA6	1.59e-06	14	147	4	CID000073553
Drug	R165481	RPS6KA4 RPS6KA1 RPS6KA3 RPS6KA6	2.86e-06	16	147	4	CID005459348
Drug	LI 4	ABCA12 LAPTM4B LSR CD82 RECK	4.43e-06	38	147	5	CID005326871
Drug	K00085	RPS6KA4 RPS6KA1 RPS6KA3 RPS6KA6	2.61e-05	27	147	4	CID009549283
Drug	AC1MS9WM	RPS6KA4 RPS6KA1 RPS6KA3 RPS6KA6	2.61e-05	27	147	4	CID003530978
Drug	DEAC	RPS6KA4 RPS6KA1 RPS6KA3 MET RPS6KA6	2.81e-05	55	147	5	CID000007277
Drug	Tenoxicam [59804-37-4]; Up 200; 11.8uM; HL60; HT_HG-U133A	KIF26B APC CLCN4 PTPRF PVR RPS6KA6 PADI1 EPHA4	4.05e-05	195	147	8	2501_UP
Drug	CS412	IARS1 IARS2	4.14e-05	2	147	2	CID006441080
Drug	BI D1870	RPS6KA1 RPS6KA3 RPS6KA6	4.19e-05	11	147	3	ctd:C516541
Drug	Flurandrenolide [1524-88-5]; Down 200; 9.2uM; PC3; HT_HG-U133A	APC LRRK1 NXT2 MAPK8IP3 MET PAFAH2 DAGLA CDON	4.20e-05	196	147	8	3679_DN
Drug	Deferoxamine mesylate [138-14-7]; Up 200; 6uM; PC3; HT_HG-U133A	CHAT NXT2 JAK3 CD82 CLCN4 CPSF1 KMT2A EPHA7	4.20e-05	196	147	8	4317_UP
Drug	Cloxacillin sodium salt [642-78-4]; Down 200; 8.8uM; PC3; HT_HG-U133A	DNAH3 FPGS ITGA10 APC SCLY MAPK8IP3 MET CDON	4.35e-05	197	147	8	2126_DN
Drug	Levopropoxyphene napsylate [5714-90-9]; Down 200; 7.4uM; MCF7; HT_HG-U133A	ATRN MAN2B1 TTC28 FPGS APC MAPK8IP3 KIDINS220 PVR	4.35e-05	197	147	8	5503_DN
Drug	Orlistat; Down 200; 10uM; PC3; HT_HG-U133A	APC LRRK1 MET PTPRD CLCN4 PVR SMARCD1 RECK	4.51e-05	198	147	8	6388_DN
Drug	Loracarbef [121961-22-6]; Up 200; 10.8uM; MCF7; HT_HG-U133A	TTC28 FPGS CHAT CD82 PAFAH2 KCNAB1 NALF2 DAGLA	4.51e-05	198	147	8	5492_UP
Drug	Epicatechin-(-) [154-23-4]; Up 200; 13.8uM; PC3; HT_HG-U133A	APC LRRK1 SLC5A1 MET PVR KCNAB1 PLCG1 PADI1	4.51e-05	198	147	8	4594_UP
Drug	17-ethynyl-5-androstene-3, 7, 17-triol	RPS6KA3 FLAD1 CNOT1 SEC23B	4.58e-05	31	147	4	ctd:C524733
Drug	Glimepiride [93479-97-1]; Up 200; 8.2uM; MCF7; HT_HG-U133A	ENPP2 JAK3 CD82 CLCN4 PVR RPS6KA6 KMT2A PLCG1	4.67e-05	199	147	8	4973_UP
Disease	primary ovarian insufficiency (implicated_via_orthology)	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P USP17L22 USP17L13	1.22e-19	46	155	13	DOID:5426 (implicated_via_orthology)
Disease	congenital heart disease (implicated_via_orthology)	USP17L21 USP17L12 USP17L20 USP17L11 USP17L24 USP17L5 USP17L10 USP17L19 USP17L18 USP17L17 USP17L6P KMT2A USP17L22 USP17L13	8.07e-19	69	155	14	DOID:1682 (implicated_via_orthology)
Disease	Coffin-Lowry syndrome (implicated_via_orthology)	RPS6KA1 RPS6KA3 RPS6KA6	5.66e-07	4	155	3	DOID:3783 (implicated_via_orthology)
Disease	Pneumoconiosis	CDH23 PTPRZ1 TMPRSS3	4.96e-05	14	155	3	C0032273
Disease	Bagassosis	CDH23 PTPRZ1 TMPRSS3	4.96e-05	14	155	3	C0004681
Disease	lysophosphatidylethanolamine 18:2 measurement	ACTL8 DAGLA MUSK	3.38e-04	26	155	3	EFO_0010369
Disease	Myasthenia Gravis	CFB MUSK	4.06e-04	6	155	2	C0026896
Disease	Myasthenia Gravis, Ocular	CFB MUSK	4.06e-04	6	155	2	C0751340
Disease	Myasthenia Gravis, Generalized	CFB MUSK	4.06e-04	6	155	2	C0751339
Disease	osteopetrosis (implicated_via_orthology)	LRRK1 CLCN4	5.66e-04	7	155	2	DOID:13533 (implicated_via_orthology)
Disease	Colorectal Neoplasms	CPAMD8 ABCA12 FPGS APC HHIP PTPRD CD226	6.80e-04	277	155	7	C0009404
Disease	leukocyte immunoglobulin-like receptor subfamily B member 4 measurement	GNPTAB CDH23	7.52e-04	8	155	2	EFO_0801768
Disease	gremlin-1 measurement	CFB TRPM1	7.52e-04	8	155	2	EFO_0020421
Disease	Nonsyndromic Deafness	CDH23 MET OTOGL TMPRSS3	8.90e-04	81	155	4	C3711374
Disease	HEPATOCELLULAR CARCINOMA	APC MET	9.63e-04	9	155	2	114550
Disease	glucose metabolism decline measurement, cingulate cortex measurement	CDH23 PHACTR1	9.63e-04	9	155	2	EFO_0007738, EFO_0009392
Disease	Hepatocellular carcinoma	APC MET	9.63e-04	9	155	2	cv:C2239176
Disease	level of Phosphatidylcholine (16:0_22:4) in blood serum	DAGLA MUSK	9.63e-04	9	155	2	OBA_2045078
Disease	phosphatidylcholine 32:0 measurement	PTPRD MUSK	1.46e-03	11	155	2	EFO_0010372
Disease	level of Sterol ester (27:1/20:5) in blood serum	DAGLA MUSK	1.46e-03	11	155	2	OBA_2045197
Disease	diverticular disease	KIF26B PIEZO1 HHIP ELFN1 TMPRSS3 SLC25A28	1.59e-03	236	155	6	EFO_0009959
Disease	cholesteryl ester 20:5 measurement	DAGLA MUSK EPHA7	1.61e-03	44	155	3	EFO_0010349
Disease	level of Phosphatidylinositol (18:0_20:3) in blood serum	DAGLA MUSK	1.75e-03	12	155	2	OBA_2045157
Disease	level of Phosphatidylcholine (O-16:0_20:4) in blood serum	DAGLA MUSK	2.06e-03	13	155	2	OBA_2045116
Disease	methylcobalamin deficiency type cblE, response to antineoplastic agent	SIT1 KMT2A	2.06e-03	13	155	2	GO_0097327, MONDO_0009354
Disease	Bardet-Biedl syndrome (is_implicated_in)	TMEM67 TTC8	2.39e-03	14	155	2	DOID:1935 (is_implicated_in)
Disease	1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3n3 or 6) measurement	DAGLA MUSK	2.39e-03	14	155	2	EFO_0022085
Disease	level of Phosphatidylcholine (18:1_18:2) in blood serum	DAGLA MUSK	2.39e-03	14	155	2	OBA_2045100
Disease	level of Phosphatidylethanolamine (18:2_0:0) in blood serum	DAGLA MUSK	2.39e-03	14	155	2	OBA_2045143
Disease	lysophosphatidylcholine 22:5 measurement	DAGLA MUSK	2.39e-03	14	155	2	EFO_0021462
Disease	asthma, response to diisocyanate	ATRN FIGN PTPN3 PTPRD EPHA4 EPHA7	2.64e-03	261	155	6	EFO_0006995, MONDO_0004979
Disease	Ciliopathies	TMEM67 ZNF423 CDH23 TTC8	2.75e-03	110	155	4	C4277690
Disease	periprosthetic osteolysis, disease progression measurement	SFMBT2 OTUD7A	2.75e-03	15	155	2	EFO_0008336, EFO_0009761
Disease	Glioblastoma Multiforme	RPS6KA3 APC MET RECK	2.84e-03	111	155	4	C1621958
Disease	Benign neoplasm of stomach	APC MET	3.54e-03	17	155	2	C0153943
Disease	Neoplasm of uncertain or unknown behavior of stomach	APC MET	3.54e-03	17	155	2	C0496905
Disease	Carcinoma in situ of stomach	APC MET	3.54e-03	17	155	2	C0154060
Disease	eicosapentaenoate EPA; 20:5n3 measurement	FZD1 MUSK	3.54e-03	17	155	2	EFO_0021049
Disease	level of Phosphatidylcholine (20:4_0:0) in blood serum	DAGLA MUSK	3.97e-03	18	155	2	OBA_2045110
Disease	Bardet-Biedl syndrome	TMEM67 TTC8	3.97e-03	18	155	2	cv:C0752166
Disease	level of Phosphatidylcholine (15:0_18:2) in blood serum	DAGLA MUSK	3.97e-03	18	155	2	OBA_2045065
Disease	Colorectal Carcinoma	DNAH3 CPAMD8 ABCA12 FPGS WRN APC HHIP PTPRD CD226 EPHA7	4.09e-03	702	155	10	C0009402
Disease	Precursor Cell Lymphoblastic Leukemia Lymphoma	FPGS JAK3 KMT2A	4.09e-03	61	155	3	C1961102
Disease	p-tau:beta-amyloid 1-42 ratio measurement	TTC28 EPHA7	4.42e-03	19	155	2	EFO_0007709
Disease	sarcopenia	RGS6 PTPRD	4.90e-03	20	155	2	EFO_1000653
Disease	exercise test	WRN PTPRD	4.90e-03	20	155	2	EFO_0004328
Disease	breast carcinoma (is_marker_for)	FZD1 CD82 PLCG1	5.11e-03	66	155	3	DOID:3459 (is_marker_for)

Protein segments in the cluster

Peptide	Gene	Start	Entry
QYTSIPLPDQLMCVI	BEST4	96	Q8NFU0
QPEETYIDPTMIQSL	C2orf16	776	Q68DN1
QVMALCTYPNLLDSP	GPT2	111	Q8TD30
FTCIVQEDMPTNPAI	ERICH6	466	Q7L0X2
ATQTYDRMQCESPPV	ELFN1	211	P0C7U0
QMCQPIPSYLIALAI	RNPEP	221	Q9H4A4
SYQIKMCPQNTSIPI	ADGRF1	446	Q5T601
QMVFPNIVNYLPCKE	ACTL8	26	Q9H568
VQVQAIPYPCFMKDN	ABCA12	1046	Q86UK0
APDYVLCSPEMQERL	ALDH3B1	246	P43353
MCPDGSYAIQENIPL	GRM3	126	Q14832
VTQLCRQYSDMPPLT	NDUFAB1	61	O14561
PLEPFLLYCNMTETA	CNTNAP4	616	Q9C0A0
APYNVMVLINTFCAP	CHRM2	401	P08172
SQLCDYINDPNMTRP	CLCN4	411	P51793
EMYPPLNQTLSQEVV	CEP76	251	Q8TAP6
EIMTVPNDPYTFLSC	DCAF6	146	Q58WW2
YIEECVQAASPMPLF	DUS3L	481	Q96G46
LRDQYNMCPDPVSLS	C7orf31	471	Q8N865
DMDPIFINLPYSTNI	CDH23	231	Q9H251
NAELMNRPEVTYPCS	CD82	161	P27701
KHPCNITEEDYQPLM	CD38	96	P28907
IESPSADPNMIYQVE	CPXCR1	31	Q8N123
PQPNYVDMLISQESC	PCDHGA7	771	Q9Y5G6
QPPEELYVCRVMDTH	PADI1	301	Q9ULC6
PEESSPNMIVYCKIE	RGS6	16	P49758
LLQRAPDYCPETMVE	RECK	66	O95980
EQPVSMSELYPLQIS	IRF2	211	P14316
IQQCMAYEPVQRPSF	JAK3	756	P52333
MECELNPRIPYTELS	KAT2A	651	Q92830
ETAMCLTERNLPIYP	PTPN3	856	P26045
ETAMCLIECNQPVYP	PTPN4	866	P29074
EVSPMPRALTEFYCQ	KBTBD3	581	Q8NAB2
PIKPNYDMTLTNACI	LTA4H	456	P09960
PSCQDSFMYDTPQEV	CFB	216	P00751
EAVYPMNCVPDVITA	FIGN	116	Q5HY92
IITPMCNPIIYSFRN	OR10AD1	281	Q8NGE0
QIEGLDQSMLPQYCT	KIDINS220	1221	Q9ULH0
PVQMSCHPELNQYIQ	MAD2L2	51	Q9UI95
QEDTRMKNVPVPVYC	MAPK8IP3	681	Q9UPT6
QNRLCLPMPIDVVYT	GNPTAB	66	Q3T906
TESDGTPLMEQYVPC	LRRK1	1151	Q38SD2
YSVARQFNMIPPVCE	KCNAB1	251	Q14722
MTPCYTANFVAPEVL	RPS6KA3	576	P51812
FYPQPLLNSSMCLED	ATRN	1036	O75882
ITVYPCIAMSPRNIQ	KIF26B	1391	Q2KJY2
PIRTYQVCNVMEPSQ	EPHA4	66	P54764
PQVVTTFELPGCYDM	CPSF1	521	Q10570
CAYPLEAMDSPVSLQ	ISM2	431	Q6H9L7
PCIYSEVMEALDLQP	PCMTD2	66	Q9NV79
VKMPCSEQNLYPVED	PARG	511	Q86W56
NVCYTLINVPMDSEP	COPB1	6	P53618
PAEPLIQMVSFEEQC	FAM205A	821	Q6ZU69
DIMSCILQNYNRPPV	VEPH1	111	Q14D04
YPIDCVKTRMQSLQP	SLC25A28	91	Q96A46
FPYRDDVMSVNPTCL	LAPTM4B	231	Q86VI4
APQCPAYAIIQELML	LRRC71	526	Q8N4P6
MQTPCFTLQYAAPEL	RPS6KA4	566	O75676
TPCYTANFVAPEVLM	RPS6KA6	581	Q9UK32
TRCPFILPDNEEMVY	NALF2	321	O75949
ECNNEQFPLEMPIYT	OTUD7A	136	Q8TE49
ETELQIPSFNEMVYP	PTPRZ1	1051	P23471
PNQLTPMRDCLYLVD	PLA2G4F	666	Q68DD2
TPIRTYQVCQVMEPN	EPHA7	66	Q15375
NPAQSDTMPCEYLSL	NCKAP1	241	Q9Y2A7
PCSYEVLQPSDIMDG	PHACTR1	206	Q9C0D0
IPLCTDIAYNQTIMP	FZD1	121	Q9UP38
SMYAPVCTVLEQALP	FZD1	171	Q9UP38
VELMAYENPNPECQS	ERVK-19	476	Q9YNA8
APFTMVPDTNYCNII	DNAH1	2186	Q9P2D7
VPDTNYCNIIVPTMD	DNAH1	2191	Q9P2D7
PVDLPTLYQDMSCNT	DNAH6	3526	Q9C0G6
TNYVLSIELPTDMPQ	DNAH3	4086	Q8TD57
CCLMQIDVTYNVPDP	CPAMD8	1486	Q8IZJ3
MYTAVPQIDPLECVN	CDON	1096	Q4KMG0
EPITLELCMNLPYNS	CORIN	456	Q9Y5Q5
GYETCPTVQPNMLNV	MAN2B1	51	O00754
QDDIESLMPIVYTPT	ME2	101	P23368
APTAQRCPTYMDVVI	ITGA10	156	O75578
QDLYCMVVPESPTSD	DAGLA	931	Q9Y4D2
QQISCPLYLCPMLEA	FPGS	271	Q05932
DEVLTPEYMGQRPCN	KMT2A	2466	Q03164
ICLPMDIDSPLSQLY	FSHR	516	P23945
SVPFAENMSLECVYP	CD226	26	Q15762
LVPYMPNAVEQASEA	FLAD1	351	Q8NFF5
YLTVNPAPRDMACQV	PKD1L1	1186	Q8TDX9
VPPFENIELYNVMCD	ENPP2	501	Q13822
VILFQPVTLPCTYQM	LSR	101	Q86X29
AIILNYTMVCPPFNE	OTOGL	2226	Q3ZCN5
VNIMPYELTRVCLQP	PTPRF	1671	P10586
LFYPCQKAEETMEQP	PAFAH2	36	Q99487
VNIMPYESTRVCLQP	PTPRD	1676	P23468
PMPIQEERFVTYVGC	TMEM67	601	Q5HYA8
LPSSEFQVNMLDCQP	NXT2	66	Q9NPJ8
VVEPRMYLSCSTNPE	MUC17	76	Q685J3
CEPDEPQVQAKIMAY	NR5A2	311	O00482
CRQVQYPLTDMSPIL	MET	1021	P08581
TLPCYLQVPNMEVTH	PVR	46	P15151
LIPCAIDQDPYFRMT	WARS1	306	P23381
QCRIYPEEMIQTGIS	ATP6V1B2	161	P21281
EPITYMQGLSACEQI	RHOF	151	Q9HBH0
ELCPYNPVMENISSI	SENP7	496	Q9BQF6
TYNITENMLCVGIVP	PRSS58	171	Q8IYP2
RCTVLLMLDYQPPQF	SMARCD1	281	Q96GM5
VVPETPCEILYQGML	STRIP2	496	Q9ULQ0
MPFYVLNIVNVVCPL	SSTR3	271	P32745
TIYPCLSPKNDQMIE	RNF8	131	O76064
CPLDMGRLNPTYEEQ	SH2D5	381	Q6ZV89
IPYIQAPMEAEAQCA	ERCC5	781	P28715
MEANQCPLVVEPSYP	SLFN11	1	Q7Z7L1
LNVMGCDLVEVSPPY	AGMAT	311	Q9BSE5
PTIIYCPSRKMTQQV	WRN	766	Q14191
PSNLAVCVNPEMQYV	IARS1	231	P41252
NPETDSIPVNDMYVI	IARS2	741	Q9NSE4
MIYPACFVLVPQSDI	MED13	276	Q9UHV7
DVDTDMCNVPYSIPR	HHIP	396	Q96QV1
EPKCLEIYPQQADAM	RIOX1	581	Q9H6W3
PNLTTDSCDPYFMLN	SLC12A4	346	Q9UP95
QPAELMPQFSTIEYV	SEC23B	106	Q15437
DDMPRVYCVEGTPIN	APC	1636	P25054
VPPLQQTLATYLQCM	CHAT	136	P28329
CDPVVLTYQAERMPE	CNOT1	1541	A5YKK6
FNEMIQPVCLPNSEE	TMPRSS3	316	P57727
YNATTPLEPEVIQAM	SCLY	36	Q96I15
DYRQMIIEPTSPCLL	TIMM50	121	Q3ZCQ8
LCTQMLEKSPYDQEP	TTC8	26	Q8TAM2
EPPALTNEMYCLVVT	TRAPPC11	761	Q7Z392
PETMENLPALYTIFQ	ZCCHC17	6	Q9NP64
LEPFIMNFINSCESP	SNX14	721	Q9Y5W7
YCLAPPINMIEEKSD	UBTD2	121	Q8WUN7
IAKNVQYPECLDMQP	USP17L18	291	D6R9N7
LETVNMCEPFYISPA	SFMBT2	306	Q5VUG0
RQDTYCPMADVIPLT	TMEM186	151	Q96B77
IAKNVQYPECLDMQP	USP17L5	291	A8MUK1
CLEAGINFMVYQPTP	MRPL18	136	Q9H0U6
IAKNVQYPECLDMQP	USP17L21	291	D6R901
IAKNVQYPECLDMQP	USP17L13	291	C9JLJ4
CNEFEMRLSEPVPQT	PLCG1	646	P19174
IAKNVQYPECLDMQP	USP17L19	291	D6RCP7
ADQIDLYAMEINPPC	TRPM1	1016	Q7Z4N2
IAKNVQYPECLDMQP	USP17L12	291	C9JPN9
PYSPVTIDQILEMVN	TTC28	1216	Q96AY4
NYMESSPEICQIPTS	ZBED6	801	P86452
PALTQVAIQYLSCPM	ZBED6	896	P86452
IAKNVQYPECLDMQP	USP17L24	291	Q0WX57
INATLQALVACPPMY	USP10	426	Q14694
TNYDVMLIDPVIPCG	UGT2A3	141	Q6UWM9
AVMDSPQQICERYPI	PSMD5	281	Q16401
PEPAVIESCMYTNTP	PIPOX	311	Q9P0Z9
SINVSVMLQPFDYDP	VAPB	66	O95292
PLAMQFISQYSPEDI	PIEZO1	2251	Q92508
PVVQPTQSFMEVYSC	ZNF423	551	Q2M1K9
IAKNVQYPECLDMQP	USP17L6P	291	Q6QN14
CTNIAYPTLVVELMP	SLC5A1	361	P13866
IAKNVQYPECLDMQP	USP17L22	291	D6RA61
IAKNVQYPECLDMQP	USP17L17	291	D6RBQ6
AEEVMCYTSLQLRPP	SIT1	121	Q9Y3P8
NCYQPLLENPMVSES	KIAA0586	61	Q9BVV6
IAKNVQYPECLDMQP	USP17L20	291	D6RJB6
IAKNVQYPECLDMQP	USP17L10	291	C9JJH3
PILLYTCEMFQDPVA	ZNF439	6	Q8NDP4
IAKNVQYPECLDMQP	USP17L11	291	C9JVI0
YMQVPVADSPNSRLC	DUSP18	66	Q8NEJ0
LMTPCYTANFVAPEV	RPS6KA1	571	Q15418
TFMCAVESYPQPEIS	MUSK	46	O15146
LSCPENCPVELYNLM	MUSK	821	O15146